Autolus Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018	2017	2016
Revenue	1.7	6.36	2.33	1.72	2.91	1.41	1.69	1.21
Revenue Growth (YoY)	-73.30%	172.96%	35.86%	-41.02%	106.68%	-16.89%	39.69%	-
Gross Profit	1.7	6.36	2.33	1.72	2.91	1.41	1.69	1.21
Selling, General & Admin	46.75	31.9	31.87	34.97	39.45	22.79	9.1	5.15
Research & Development	130.48	117.35	110.84	134.89	105.42	36.15	16.01	10.44
Other Operating Expenses	4.17	0.52	0.68	0	4.1	0	0	0
Operating Expenses	181.4	149.77	143.38	169.86	148.97	58.94	25.11	15.59
Operating Income	-179.7	-143.41	-141.05	-168.15	-146.06	-57.53	-23.42	-14.38
Interest Expense / Income	45.07	8.91	1.11	0	0	0	0	0
Other Expense / Income	-16.37	-3.75	-0.12	-1.89	-7.06	-5.5	-0.04	-0.05
Pretax Income	-208.4	-148.57	-142.04	-166.26	-139.01	-52.03	-23.38	-14.33
Income Tax	-0.02	0.27	0.06	-24.16	-15.16	-7.28	-3.65	-1.78
Net Income	-208.38	-148.84	-142.1	-142.09	-123.85	-44.75	-19.73	-12.55
Shares Outstanding (Basic)	174	95	72	52	43	32	14	10
Shares Outstanding (Diluted)	174	95	72	52	43	32	14	10
Shares Change	83.11%	31.78%	39.81%	19.72%	36.47%	128.95%	38.76%	-
EPS (Basic)	-1.20	-1.57	-1.97	-2.76	-2.88	-1.42	-1.43	-1.26
EPS (Diluted)	-1.20	-1.57	-1.97	-2.76	-2.88	-1.42	-1.43	-1.26
Free Cash Flow	-156.57	-123.15	-126.72	-132.44	-119.83	-40.66	-19.24	-11.7
Free Cash Flow Per Share	-0.90	-1.30	-1.76	-2.57	-2.78	-1.29	-1.40	-1.18
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Operating Margin	-10583.10%	-2254.84%	-6053.65%	-9804.37%	-5022.83%	-4089.05%	-1383.23%	-1186.14%
Profit Margin	-12272.26%	-2340.24%	-6098.54%	-8285.36%	-4258.91%	-3180.60%	-1165.21%	-1035.48%
Free Cash Flow Margin	-9221.02%	-1936.31%	-5438.54%	-7722.39%	-4120.53%	-2889.55%	-1136.21%	-965.68%
EBITDA	-152.71	-128.81	-128.75	-160.6	-134.4	-50.32	-22.37	-13.85
EBITDA Margin	-8993.64%	-2025.28%	-5525.62%	-9364.37%	-4621.63%	-3576.55%	-1321.38%	-1142.66%
Depreciation & Amortization	10.62	10.85	12.19	5.66	4.61	1.71	1.01	0.48
EBIT	-163.34	-139.66	-140.93	-166.26	-139.01	-52.03	-23.38	-14.33
EBIT Margin	-9619.26%	-2195.94%	-6048.63%	-9694.29%	-4780.19%	-3698.01%	-1380.98%	-1182.10%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).